Get the Stockscreener App
212.56
0.21%
-0.44
After Hours:
212.56
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $212.56, with a volume of 4.47M.
It is down -0.21% in the last 24 hours and up +7.06% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$213.00
Open:
$212.55
24h Volume:
4.47M
Relative Volume:
0.85
Market Cap:
$375.50B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
101.22
EPS:
2.1
Net Cash Flow:
$18.24B
1W Performance:
+1.03%
1M Performance:
+7.06%
6M Performance:
+0.48%
1Y Performance:
+10.21%
1-Day Range:
$211.00
$214.34
1-Week Range:
$208.99
$214.34
52-Week Range:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
212.56 | 376.28B | 58.33B | 3.73B | 18.24B | 2.10 |
|
LLY
Lilly Eli Co
|
727.21 | 665.99B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.43 | 430.51B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
129.73 | 248.60B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.71 | 209.94B | 63.43B | 16.42B | 14.72B | 6.49 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie’s Latest Study on Parkinson’s Treatment: What Investors Need to Know - TipRanks
AbbVie’s New Study on Risankizumab: A Potential Game-Changer for Ulcerative Colitis? - TipRanks
How to use a screener to detect AbbVie Inc. breakoutsGap Down & Verified Momentum Stock Watchlist - Newser
AbbVie (ABBV) Declares US$1.64 Quarterly Dividend for Shareholders - Yahoo Finance
AbbVie’s Phase 3b Study on Elagolix: A Potential Game-Changer for Endometriosis Treatment? - TipRanks
AbbVie declares quarterly dividend of $1.64 per share By Investing.com - Investing.com South Africa
Is AbbVie Inc. a good stock for dollar cost averaging2025 Sector Review & Fast Exit and Entry Strategy Plans - خودرو بانک
Verizon, Essex Property Trust, Broadcom, Sachem Capital, AbbVie, Nucor Announce Dividend Increases - AInvest
Abbvie Inc. Declares Quarterly Dividend, Payable on November 14, 2025 - MarketScreener
AbbVie Inc. Announces Quarterly Dividend of $1.64 per Share - AInvest
AbbVie Incdeclares quarterly dividend of $1.64 per share - MarketScreener
Is AbbVie Inc. stock undervalued right nowQuarterly Risk Review & Entry Point Strategy Guides - خودرو بانک
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie declares quarterly dividend of $1.64 per share - Investing.com
AbbVie Keeps Quarterly Dividend at $1.64 a Share, Payable Nov. 14 to Shareholders of Record as of Oct. 15 - MarketScreener
Will AbbVie Inc. outperform the market in YEARGold Moves & Low Risk Growth Stock Ideas - خودرو بانک
Stock Analysis | Abbvie OutlookTechnical Neutrality and Strong Fundamentals Amid Mixed Analyst Ratings - AInvest
AbbVie Inc. Added to Custom Quant Screener TodayJuly 2025 Decliners & Weekly Top Performers Watchlists - Newser
Intraday pattern recognizer results for AbbVie Inc.Sell Signal & Capital Efficiency Focused Ideas - Newser
AbbVie Inc. (NYSE:ABBV) Is a Favorite Amongst Institutional Investors Who Own 74% - 富途牛牛
AbbVie’s ABBV-400 Study: A New Hope for Advanced Solid Tumors - TipRanks
AbbVie’s New Study on Risankizumab: Implications for Psoriatic Arthritis Treatment - TipRanks
Opinions September 4, 2025 - The Indiana Lawyer
AbbVie’s Real-World Study on Epcoritamab: A Potential Game-Changer in Lymphoma Treatment - TipRanks
AbbVie Advances Pediatric Infection Treatment with New Clinical Study - TipRanks
Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth? - sharewise.com
Is AbbVie Inc. stock overvalued or fairly pricedJuly 2025 Update & Verified Chart Pattern Signals - خودرو بانک
AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial - Yahoo Finance
Health Canada approves AbbVie’s Elahere for ovarian cancer - Yahoo Finance
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? - The Motley Fool
Is AbbVie Stock Underperforming the S&P 500? - MSN
7th Circ. Backs AbbVie's Win Against Ex-Sales Rep's FCA Suit - Law360
AbbVie’s $0.84 Billion Volume Tumbles to 100th as Regulatory Uncertainty and Biosimilar Delays Weigh on Investor Sentiment - AInvest
Genmab/AbbVie’s Epkinly Could Get Competitive Edge With Outpatient Option - insights.citeline.com
AbbVie Beats Employee’s Would-Be Whistleblower Suit on Appeal - Bloomberg Law News
AbbVie (ABBV) Advances Cancer Treatments With Epcoritamab And Mirvetuximab Approvals - Yahoo Finance
Will AbbVie Inc. bounce back from current supportEarnings Risk Summary & High Accuracy Trade Signal Alerts - Newser
AstraZeneca attorney says state 340B laws will ‘topple’ the federal drug discount program - Endpoints News
AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting - Seeking Alpha
AbbVie reports positive results for outpatient lymphoma treatment - Investing.com
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Investing News Network
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - PR Newswire
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers - AbbVie News Center
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Quantitative breakdown of AbbVie Inc. recent moveTrade Signal Summary & Daily Profit Maximizing Tips - Newser
Combining machine learning predictions for AbbVie Inc.Stop Loss & Fast Gaining Stock Strategy Reports - Newser
AbbVie’s Strategic Acquisitions and Trial Success Fuel 0.72% Rally Despite 102nd-Ranked 920M Volume - AInvest
Is AbbVie Inc. impacted by rising ratesRisk Management & Fast Exit and Entry Trade Guides - خودرو بانک
Strategic Implications of AbbVie’s Elahere Approval in Canada: A New Era for Oncology Growth and Market Access - AInvest
AbbVie's Elahere gains approval in Canada for ovarian cancer - Seeking Alpha
Visual trend scoring systems applied to AbbVie Inc.Trade Entry Summary & Real-Time Buy Zone Alerts - Newser
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):